Literature DB >> 22544694

HIV genotype resistance testing in antiretroviral (ART) exposed Indian children--a need of the hour.

Ira Shah1, Shefali Parikh.   

Abstract

Development of drug resistance in HIV infected children with treatment failure is a major impediment to selection of appropriate therapy. HIV genotype resistance assays predict drug resistance on the basis of mutations in the viral genome. However, their clinical utility, especially in a resource limited setting is still a subject of debate. The authors report two cases in which both the children suffered from treatment failure of various antiretroviral therapy regimes. In both the cases, Genotype Resistance Testing (GRT) prompted a radical change from proposed failure therapy as per existing guidelines. GRT was specifically important for the selection of a new dual Nucleoside reverse transcriptase inhibitors (NRTI) component of failure regimen by identifying TAMS and M184V mutations in the HIV genome. These case reports highlight the importance of GRT in children failing multiple antiretroviral regimes; and emphasizes the need to recognize situations where GRT is absolutely essential to guide appropriate therapy, even in a resource limited setting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544694     DOI: 10.1007/s12098-012-0752-6

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  8 in total

1.  Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group.

Authors:  W T Shearer; T C Quinn; P LaRussa; J F Lew; L Mofenson; S Almy; K Rich; E Handelsman; C Diaz; M Pagano; V Smeriglio; L A Kalish
Journal:  N Engl J Med       Date:  1997-05-08       Impact factor: 91.245

2.  Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.

Authors:  Cristina Tural; Lidia Ruiz; Christopher Holtzer; Jonathan Schapiro; Pompeyo Viciana; Juan González; Pere Domingo; Charles Boucher; C Rey-Joly; Bonaventura Clotet
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

3.  High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings.

Authors:  N Kumarasamy; Vidya Madhavan; Kartik K Venkatesh; S Saravanan; Rami Kantor; P Balakrishnan; Bella Devaleenal; S Poongulali; Tokugha Yepthomi; Suniti Solomon; Kenneth H Mayer; Constance Benson; Robert Schooley
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

4.  Drug resistance mutations in HIV type 1 isolates from naive patients eligible for first line antiretroviral therapy in JJ Hospital, Mumbai, India.

Authors:  Alake Deshpande; Surendra Karki; Patricia Recordon-Pinson; Herve J Fleury
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-16       Impact factor: 2.205

5.  Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.

Authors:  P Clevenbergh; J Durant; P Halfon; P del Giudice; V Mondain; N Montagne; J M Schapiro; C A Boucher; P Dellamonica
Journal:  Antivir Ther       Date:  2000-03

6.  Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

Authors:  Antonella Cingolani; Andrea Antinori; Maria Gabriella Rizzo; Rita Murri; Adriana Ammassari; Francesco Baldini; Simona Di Giambenedetto; Roberto Cauda; Andrea De Luca
Journal:  AIDS       Date:  2002-02-15       Impact factor: 4.177

7.  High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India.

Authors:  Sourav Sen; Srikanth P Tripathy; Ajit A Patil; Vaishali M Chimanpure; Ramesh S Paranjape
Journal:  AIDS Res Hum Retroviruses       Date:  2007-10       Impact factor: 2.205

8.  Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India.

Authors:  Madhavan Vidya; Shanmugam Saravanan; Shanmugasundaram Uma; Nagalingeswaran Kumarasamy; Solomon S Sunil; Rami Kantor; David Katzenstein; Bharat Ramratnam; Kenneth H Mayer; Solomon Suniti; Pachamuthu Balakrishnan
Journal:  Antivir Ther       Date:  2009
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.